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a b s t r a c t
Antimalarial chloroquine is also used for the treatment of immune-mediated diseases. The interference
of chloroquine with interferon-γ-induced tryptophan breakdown and neopterin production has been
investigated in human peripheral bloodmononuclear cells (PBMC) in vitro. Micromolar concentrations
(2–50 μM) of chloroquine dose-dependently suppressed mitogen-induced tryptophan breakdown in
PBMC but not in the myelomonocytic THP-1-Blue cell line, after 48 h of treatment. In stimulated PBMC,
neopterin production was super-induced by 10 μM chloroquine, while it was signiﬁcantly suppressed
at a concentration of 50 μM. These anti-inﬂammatory effects may relate to the therapeutic beneﬁt of
chloroquine in inﬂammatory conditions and may widen the spectrum of its clinical applications.
c© 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Since the 1930s, chloroquine [(RS)-N′-(7-chloroquinolin-4-yl)-
N,N-diethyl-pentane-1,4-diamine] is awidely used antimalarial drug,
mainlydue to its relatively good tolerability and the cost-efﬁcient syn-
thesis [1,2]. Upon cellular uptake, chloroquine accumulates in acidic
organelles such as endosomes, lysosomes and in Golgi vesicles, where
it interferes with the activity of enzymes and posttranslational pro-
tein modiﬁcation steps [3,4]. Furthermore, drug accumulation de-
creases the intracellular iron concentration and induces oxidative
stress [5,6]. Accumulated in the digestive vacuoles of parasite affected
cells, chloroquine inhibits themalaria parasite’s digestive pathway for
hemoglobin [7]. The development of resistant Plasmodium strains has
now led to the replacement of the ﬁrst-line treatment and prophy-
laxis with chloroquine and its derivatives with other therapeutics
such as artesimin [8,9]. However, chloroquine and analogs became
interesting as treatment options for other immune-related disorders,
due to their immunomodulatory properties, e.g. by interfering with
pro-inﬂammatory cytokine secretion [10,11]. On the basis of its anti-
inﬂammatory properties, chloroquine and hydroxychloroquine are
used for the treatment of rheumatoid arthritis, discoid lupus erythe-
matosus, amebic hepatitits and chronic Q fever [2,12–15].* Corresponding author at: Division of Biological Chemistry, Biocenter, Innsbruck
Medical University, Rm 4-313, Innrain 80, 6020 Innsbruck, Austria. Tel.: +43 512 9003
70350; fax: +43 512 9003 73330.
E-mail address: dietmar.fuchs@i-med.ac.at (D. Fuchs).
2211-5463 c© 2012 Federation of European Biochemical Societies. Published by Elsevier B.V
http://dx.doi.org/10.1016/j.fob.2012.08.004The pro-inﬂammatory cytokine interferon-γ (IFNγ) plays a cen-
tral role in the cellular immune response, as it induces several
immune-regulatory pathways and cellular responses [16,17]. Inﬂam-
mation is further characterized through the activation of the redox-
sensitive transcription factor nuclear factor-kappa B (NF-κB). NF-κB
regulates a variety of genes that control immune responses suchas the
pro-inﬂammatory cytokines [18]. IFNγ stimulates also the produc-
tion of neopterin by guanosine triphosphate (GTP)-cyclohydrolase-I
(GTP-CH-I, EC 3.5.4.16) in macrophages [19]. Likewise, neopterin was
found to support oxidation processes by reactive oxygen and chlo-
ride metabolites [20] as well as their formation in inﬂammatory cells
like neutrophils [21]. In turn, in target cells redox-sensitive signal-
ing cascades such as nuclear factor-κB are triggered by neopterin
[22]. IFNγ signaling is also involved in the activation of indoleamine
2,3-dioxygenase (IDO, EC 1.13.11.52), the enzyme that catalyses the
rate-limiting step in the conversion of tryptophan to kynurenine [23].
Neopterin levels, tryptophan concentrations and IDO activity have
been successfully used to monitor cell-mediated immune activation
and to reveal prognostic information in a variety of diseases, including
rheumatoid arthritis [24–26].
Elevated concentrations of urine and serum neopterin have been
detected in patients infected with Plasmodium falciparum and Plas-
modium vivax from epidemiologically distinct populations [27–30].
Similarly, increased breakdown of tryptophan has been reported in a
murine malaria model [31].
A more detailed analysis of potential interactions of chloroquine
with interferon-γ-induced tryptophan breakdown and neopterin.Open access under CC BY-NC-ND license.
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Table 1
Concentrations of tryptophan, kynurenine, kynurenine to tryptophan ratio (Kyn/Trp)
and neopterin in the supernatant of unstimulated PBMC and in cells stimulatedwith 10
μg/ml PHA for 48 h. Results shown are the mean values ± SEM of three independent
experiments run in duplicates.
Tryptophan
(μM)
Kynurenine
(μM)
Kyn/Trp
(μmol/
mmol) Neopterin (nM)
Unstimulated
29.9 ± 6.2 2.4 ± 0.9 99.2 ± 46.6 3.8 ± 0.1
PHA (10
μg/ml)
1.9 ± 1.1* 14.3 ± 0.7* 12408 ±
4379*
20.1 ± 1.4*
∗ p < 0.05, compared to unstimulated cells.
2.5. Measurement of tryptophan, kynurenine, neopterin and sIL-2Rα
concentrationsproduction might help to explain the beneﬁcial effects for the treat-
ment of rheumatic diseases and might introduce new therapeutic
regimen for disorders that are associated with increased immune ac-
tivation.
Therefore, the aim of this in vitro study was to investigate the
immunomodulatory properties of chloroquine in human peripheral
blood mononuclear cells (PBMC) and in THP-1-Blue cells. Mitogen-
stimulated PBMC represent a widely usedmodel to evaluate pro- and
anti-inﬂammatory properties of compounds, where neopterin pro-
duction and tryptophan degradation can be used as read-outs [32].
The THP-1-Blue cell line is transfected with a NF-κB/AP-1-inducible
reporter system that allows the monitoring of NF-κB activity in cell
supernatants. In this cell line, lipopolysaccharide (LPS)-induced NF-
κB expression has been reported to correlate with neopterin produc-
tion and IDO activity [33]. Further, the production of soluble inter-
leukin 2 receptor alpha (sIL-2Rα) was used to monitor the inﬂuence
of chloroquine on the inﬂammatory process [32,34].Tryptophan, kynurenine, neopterin and cytokine measurements
wereperformed in centrifuged supernatants. Tryptophanandkynure-
nine concentrationsweremeasured by high performance liquid chro-
matography (HPLC) using 3-nitro-l-tyrosine as an internal standard
[35]. To estimate IDO activity, Kyn/Trp was calculated and expressed
as μmol kynurenine/mmol tryptophan.
Neopterin concentrations were determined by ELISA (BRAHMS,
Hennigsdorf, Berlin, Germany) with a detection limit of 2 nM, IL-
2Rα concentrations were measured by ELISA obtained from R&D
(Biomedica, Vienna, Austria), both according to the manufacturer’s
instructions.
2.6. Measurement of NF-κB activity and cell viability in THP-1-Blue
cells
THP-1-Blue cells are stably transfected with a reporter plasmid
expressing the secreted embryonic alkaline phosphatase (SEAP) un-
der the control of a NF-κB/AP-1 inducible promoter. Upon NF-κB
activation, SEAP is expressed and released into the media, where the
enzyme activity has been measured in a colorimetric assay at 635
nm (Bio-Tek Instruments, Bad Friedrichshall, Germany) by incubat-
ing10% (v/v) of cell supernatantwith90% (v/v) ofQuanti-Blue reagent
(Invivogen, San Diego, USA).
Cell viability was measured by CellTiter-Blue® assay (Promega,
Vienna, Austria) according to the manufacturer’s instructions.
2.7. Statistical analysis
For statistical analysis, the Statistical Package for the Social Sci-
ences (version 19, SPSS, Chicago, Ill, USA) was used. Because not all
data sets showednormal distribution, for comparison of grouped data
non-parametric Friedman test and Wilcoxon signed-ranks test were
applied. p-Values below 0.05 were considered to indicate signiﬁcant
differences.
3. Results
3.1. Effect of chloroquine on tryptophan metabolism and neopterin
formation in PBMC
After an incubation period of 48 h, neopterin concentrations
(± SEM) in culture supernatants of unstimulated PBMC were 3.8
± 0.1 nM and the mean Kyn/Trp ratio was 99.2 ± 46.6 μmol/
mmol. Upon stimulation of cells with the phytohemagglutinin (PHA),
neopterin production increased to 20.1 ± 1.4 nM and the mean
Kyn/Trp was increased approximately 100-fold. The concentrations
of neopterin, tryptophan, kynurenine and IDO activity, indicated by
Kyn/Trp, in unstimulated and PHA-stimulated PBMC are listed in Ta-
ble 1.2. Materials and methods
2.1. Chemicals
Lipopolysaccharide (LPS) of Escherichia coli, phytohemagglutinin
(PHA) and chloroquine were obtained from Sigma–Aldrich (Vienna,
Austria). The latter was dissolved in RPMI 1640 medium (MedPro,
Vienna, Austria) before each experiment.
2.2. Isolation and culture of human PBMC
PBMC were isolated from whole blood obtained from healthy
donors by density centrifugation (Lymphoprep, Nycomed Pharma
AS, Oslo, Norway). After isolation, PBMC were washed three times
in phosphate buffered saline containing 0.5 mM EDTA. Cells were
maintained in RPMI 1640 supplemented with 10% heat-inactivated
fetal calf serum (FCS, Biochrom, Berlin, Germany), 2 mM l-glutamine
(Serva, Heidelberg, Germany) and 50 μg/ml gentamicin (Bio-
Whittaker, Walkersville, MD) at 37 ◦C with 5% CO2.
2.3. THP-1-Blue cell culture
THP-1-Blue cells (Invivogen, San Diego, USA)were incubated at 37
◦C with 5% CO2 in RPMI 1640 medium supplemented with 10% FCS
and 200 μg/ml zeocin (Invivogen, San Diego, USA).
2.4. Cell treatment
PBMC were seeded at a density of 1.5 × 106 cells/ml in supple-
mentedRPMI 1640, preincubated for 30minwith orwithout different
concentrations of chloroquine (2.0–50 μM) and stimulated, or not,
with 10μg/ml PHA for another 48 h. THP-1-Blue cells were seeded at
a density of 5 × 105 cells/ml in supplemented RPMI 1640. Cells were
preincubated for 30minwith different concentrations of chloroquine
(6.25–50 μM) and stimulated or not with 1 μg/ml LPS.
Supernatants for Kyn/Trp determination were collected after 48
h, after this period the accumulated tryptophan breakdown and
neopterin formation reaches a plateau [32]. Supernatants from THP-
1-Blue cells for NF-κB activity measurement were collected for both,
24 and 48 h treatment duration. However, in agreement with earlier
observations, the read-out at 24 h was able to better discriminate
results obtained with different concentrations of compounds [33].
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Fig. 1. Effect of 48 h of chloroquine treatment on tryptophan (A) and kynurenine (B) concentrations, on IDO activity expressed as kynurenine to tryptophan ratio (Kyn/Trp)
(C) and on neopterin production (D) in unstimulated (white bars) and PHA-stimulated PBMC (black bars), expressed as % of baseline (control cells treated with or without PHA,
respectively). Results shown are the mean values ± SEM of three independent experiments run in duplicates (*p < 0.05, compared to cells without added chloroquine).
In unstimulated cells, tryptophan concentrations were not af-
fected by chloroquine addition (2.0–50 μM of chloroquine, Fig. 1A),
but kynurenine levels decreased in a dose-dependent manner (Fig.
1B). In PHA-stimulated PBMC, chloroquine suppressed tryptophan
breakdown in a dose-dependent manner (Fig. 1A) and in parallel
kynurenine levels declined (Fig. 1B). A reduction of the Kyn/Trp upon
chloroquine treatment was dose-dependent in both, unstimulated
and PHA-stimulated PBMC, with a more pronounced effect in PHA-
stimulated cells (Fig. 1C).
The addition of chloroquine to unstimulated PBMC resulted in an
only slight suppression of neopterin concentrations in culture su-
pernatants, e.g. 20 μM chloroquine suppressed neopterin produc-
tion (± SD) to 93.8 ± 3.5% of baseline. In PHA-stimulated cells, the
neopterin formation was signiﬁcantly increased at a concentration of
10 μM chloroquine (124.5 ± 4.0%), while 50 μM of chloroquine re-
sulted in a strong decrease of neopterin concentrations down to 29.0
± 10.4% compared to PHA-stimulated control cells (Fig. 1D).
3.2. Effect of chloroquine on sIL2Rα secretion in PHA-stimulated PBMC
IL2Rα concentrations in cell culture supernatants were increased
more than 100-fold in PHA-stimulated PBMC in comparison to un-
stimulated cells (p < 0.005), additional chloroquine treatment (10
and 50 μM) reduced this effect in a dose-dependent manner (p <
0.05 and 0.005 for 10 and 50 μM chloroquine- and PHA-stimulated
PBMC in comparison to PHA-stimulated control, details not shown).
3.3. Effects of chloroquine in THP-1-Blue cells
Cytotoxicity of chloroquine was evaluated in THP-1-Blue cells
treated with increasing doses for 24 h, with or without additional
stimulationby lipopolysaccharide (LPS). Treatment resulted in adose-
dependent decrease of cell viability with IC50 values of 63.16 μM in
unstimulated and 54.35 μM in stimulated cells.
After an incubation of 48 h, the Kyn/Trp (± SEM) was signiﬁ-
cantly increased in LPS-stimulated THP-1-Blue cells (96.4 ± 12.6
μmol/mmol) in comparison to unstimulated cells (20.4 ± 1.1μmol/
mmol). Therewas no effect onKyn/Trp upon treatment of THP-1-Blue
cellswith chloroquine forboth, LPS-stimulatedandunstimulatedcells
(data not shown).
Upon 24 h of LPS stimulation, the activation of NF-κB according
to SEAP activity was increased (9.60 ± 1.18 (SEM)-fold) in compari-
son to unstimulated cells (p < 0.005). The additional treatment with
chloroquine decreased SEAP activity in a dose-dependent manner in
LPS-stimulated cells (SEAP activity expressed as fold of unstimulated
control: 12.5 μM = 6.77 ± 0.84, 50 μM = 4.24 ± 0.63, p < 0.005),
while unstimulated cells were not affected (Fig. 2).
4. Discussion
In this study, the capacity of chloroquine to modulate immune
responses in human PBMC and in myelomonocytic THP-1-Blue cells
was investigated in vitro. In PBMC, both stimulated or not with the
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Fig. 2. Effect of chloroquine on the enzyme secreted embryonic alkaline phosphatase
(SEAP) as a measure of nuclear factor-kappa B (NF-κB) activation in unstimulated
(white bars) and lipopolysaccharide (LPS)-stimulated (black bars) THP-1-Blue cells,
after 24 h of treatment. Results shown are the mean values ± SEM of six independent
experiments performed in duplicates (**p< 0.005, compared to baseline= control cells
treated with or without LPS, respectively).
mitogen PHA, chloroquine reduced Kyn/Trp effectively and in a dose-
dependent manner already at low concentrations. Also, IL-2Rα se-
cretion was decreased in mitogen-stimulated cells upon chloroquine
treatment.
In agreement with our study, a variety of effects of antimalarial
drugs on immune-mediated mechanisms have been described such
as the suppression of pro-inﬂammatory cytokine production. Chloro-
quine has been shown to decrease tumor necrosis factor-α (TNF-α),
IFNγ, interleukin-1 (IL-1) and 6 (IL-6) secretion PBMC and malaria
patient blood samples [9,11], to reduce monocyte receptor expres-
sion [36] and to regulate monocyte GTP-cyclohydrolase-1 expression
[37].
Only recently, He et al. reported a new mechanism underlying
the anti-inﬂammatory activity of chloroquine, whereby glucocorti-
coid signaling is activated and thereby promotes the transrepres-
sion of pro-inﬂammatory cytokines in a mouse collagen-induced
arthritis model [38]. Our ﬁnding, that chloroquine interferes with
T-helper cell type-1 immune response in vitro by repressing tryp-
tophan breakdown in PHA-stimulated PBMC at low micromolar con-
centrations, represents an additional strategy to inhibit inﬂammation.
Other nonsteroidal anti-inﬂammatory substances, such as acetylsali-
cylic acid, and corticosteroid drugs, such as prednisolone, have been
reported to inhibit tryptophan breakdown and also neopterin pro-
duction [39,40]. Interestingly, in our study, neopterin production de-
creased signiﬁcantly only at the highest dose of 50 μM chloroquine
in PHA-stimulated PBMC, while it was signiﬁcantly increasedwith 10
μM.
Of note, chloroquine had no effects on the tryptophanmetabolism
in unstimulated as well as LPS-stimulated THP-1-Blue cells at the
tested concentrations. In LPS-stimulated THP-1-Blue cells, chloro-
quinewas able to reduceNF-κB/AP-1driven reporter geneexpression
in a dose-dependent manner. The decrease of NF-κB activation goes
in parallel with a decrease in cell viability. Cepika et al. reported that
chloroquine had no effect at low micromolar concentrations (2 μM)
in monocyte populations of PBMC upon LPS challenge, and suggested
that chloroquine regulation of cytokine secretion in monocytes is ex-
erted only at high toxic concentrations, while lower doses affect other
signalingpathways andupregulationof costimulatorymolecules [41].
On the contrary to monocytes, in human astroglial cells, chloroquine
alone, without additional stimulus, was able to induce activation of
NF-κB and subsequent expression of pro-inﬂammatory genes [42].
Therefore, the effect of chloroquine on NF-κB activation remains elu-
sive.
In conclusion, our in vitro study shows that chloroquine treat-
ment results in the suppression of distinct mechanisms in mitogen-
stimulated PBMC in comparison to toll like receptor (TLR) stimulated
monocytic THP1-Blue cells. Data indicates that chloroquine might
have stronger inﬂuence on IDO activity by acting on cytokine secre-
tion of T-cells than by acting on THP-1-Blue monocytes. Although
THP-1-Blue cells are at an advanced stage of myelomonocytic devel-
opment and their responsiveness to LPS has been extensively exam-
ined, they represent an undifferentiated phenotype [33,43]. The use
of macrophages that have an exaggerated response to LPS and act dif-
ferently than monocytes, might give more insight into chloroquine’s
mode of action.
However, our ﬁndings might be of importance for the discussion
about the use of chloroquine for the treatment of other disorders
associated with overwhelming immune response. The application
of chloroquine and its analogs has already been proved efﬁcient in
the treatment studies of autoimmune disease, e.g. in systemic lupus
erythomatosus [12,13]. Furthermore, there are clinical trials ongoing
with chloroquine and its derivatives that explore their potential for
the treatment of viral infections and cancer, with human immunode-
ﬁciency virus (HIV) infection being the most studied disease [44–47].
Our results support the view that a more detailed analysis of chloro-
quine activities in further in vitro and in vivo studies will be of cen-
tral importance to explore additional potential therapeutic regimes in
other chronic inﬂammatory conditions such as coronary heart disease
or neurodegeneration.
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